MCM5及Ki-67蛋白表达与乳腺癌新辅助化疗近期疗效关系的研究

The Relationship between Expression of MCM5 and Ki-67 and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

目的:探讨人乳腺癌新辅助化疗前后MCM5和Ki-67蛋白的表达状况,分析其与化疗疗效关系的意义。方法:采用免疫组化法检测40例乳腺癌新辅助化疗前后标本中MCM5和Ki-67的表达。结果:新辅助化疗有效率为77.5%。化疗前MCM5和Ki-67蛋白阳性表达显著高于化疗后(P<0.01);化疗前MCM5蛋白阳性表达显著高于Ki-67(P<0.01)。化疗有效组(31例)。MCM5蛋白阳性表达显著高于无效组(9例)(P<0.01);化疗有效组Ki-67蛋白阳性表达高于无效组,但差异无显著性(P>0.05)。化疗前MCM5、Ki-67表达呈正相关(r=0.601,P<0.01)。结论:ET方案新辅助化疗有较好的疗效,可能通过抑制MCM5、Ki-67蛋白的表达来阻止乳腺癌细胞的增殖。MCM5蛋白高表达者化疗更为敏感,MCM5可作为临床指导乳腺癌化疗并预测化疗敏感性的分子生物学指标之一。

Objective： To study the expression levels of MCM5 and Ki-67 before and after neoadjuvant chemotherapy in breast cancer patients and to analyze the relationship between these expression levels and patient response to neoadjuvant chemotherapy. Methods： The expression levels of MCM5 and Ki-67 before and after neoadjuvant chemotherapy were examined by immunohistochemistry in 40 cases of breast cancer. Resuits： The overall response rate to neoadjuvant chemotherapy was 77.5%. The positive expression of MCM5 and Ki-67 before neoadjuvant chemotherapy was significantly higher than that after neoadjuvant chemotherapy （P〈0.01）. The positive expression of MCM5 was significantly higher than that of Ki-67 in breast cancer before neoadjuvant chemotherapy （P〈0.01）. Positive MCM5 expression in the group that responded to neoadjuvant chemotherapy was significantly higher than that in the group that did not respond to neoadjuvant chemotherapy （P〈0.01）. No significant difference was found in Ki-67 expression between the group that responded and the group that did not respond to neoadjuvant chemotherapy （P〉0.05）. Before neoadjuvant chemotherapy, the expression of MCM5 was positively correlated with the expression of Ki-67 （r=0.601, P〈0.01）. Conclusion： A regimen including neoadjuvant chemotherapy with ET is effective and may inhibit the proliferation of breast cancer cells by downregulating the expression of MCM5 and Ki-67. Patients with high expression of MCM5 are more likely to respond to chemotherapy. The expression of MCM5 as a biological marker could be used as a prognostic factor indicating a more favorable response to chemotherapy in breast cancer patients.